Literature DB >> 34171330

Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy.

Lisa Dannenberg1, Sarah Weske2, Malte Kelm3, Bodo Levkau2, Amin Polzin3.   

Abstract

Diabetes mellitus (DM) is associated with a specific cardiac phenotype characterized by structural and functional alterations. This so-called diabetic cardiomyopathy (DM CM) is clinically relevant as patients with DM show high incidence of heart failure. Mechanistically, several parameters interact on the cardiomyocyte level leading to increased inflammation, apoptosis, reactive oxygen species and altered calcium signaling. This in turn provokes functional myocardial changes that might inter alia play into the worsened clinical outcome in DM patients. Therefore, efficient therapeutic options are urgently needed. This review focuses on mechanistic effects of currently recommended antidiabetic treatment and heart failure therapy for DM CM.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac dysfunction; Cardiomyopathy; Diabetes; Hyperglycemia; Outcome

Mesh：

Year:  2021        PMID： 34171330     DOI： 10.1016/j.pharmthera.2021.107920

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  7 in total

Review 1.  Update on Management of Cardiovascular Diseases in Women.

Authors:  Fabiana Lucà; Maurizio Giuseppe Abrignani; Iris Parrini; Stefania Angela Di Fusco; Simona Giubilato; Carmelo Massimiliano Rao; Laura Piccioni; Laura Cipolletta; Bruno Passaretti; Francesco Giallauria; Angelo Leone; Giuseppina Maura Francese; Carmine Riccio; Sandro Gelsomino; Furio Colivicchi; Michele Massimo Gulizia
Journal:  J Clin Med       Date:  2022-02-22       Impact factor: 4.241

2.  Effect of Mineralocorticoid Receptor Antagonists on the Prognosis of Patients with Ventricular Tachyarrhythmias.

Authors:  Tobias Schupp; Max von Zworowsky; Linda Reiser; Mohammad Abumayyaleh; Kathrin Weidner; Kambis Mashayekhi; Thomas Bertsch; Mohammed L Abba; Ibrahim Akin; Michael Behnes
Journal:  Pharmacology       Date:  2021-12-08       Impact factor: 2.547

3.  Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.

Authors:  Egle Corrado; Giuseppe Dattilo; Giuseppe Coppola; Claudia Morabito; Enrico Bonni; Luca Zappia; Giuseppina Novo; Cesare de Gregorio
Journal:  Eur J Clin Pharmacol       Date:  2021-09-23       Impact factor: 2.953

4.  Galectin-3 Inhibition Ameliorates Streptozotocin-Induced Diabetic Cardiomyopathy in Mice.

Authors:  Ning Zhu; Liuyan Zhu; Bingwu Huang; Wenjun Xiang; Xuyong Zhao
Journal:  Front Cardiovasc Med       Date:  2022-04-26

5.  Concurrent Use of Oral Anticoagulants and Sulfonylureas in Individuals With Type 2 Diabetes and Risk of Hypoglycemia: A UK Population-Based Cohort Study.

Authors:  Hassan Alwafi; Ian C K Wong; Abdallah Y Naser; Amitava Banerjee; Pajaree Mongkhon; Cate Whittlesea; Alaa Alsharif; Li Wei
Journal:  Front Med (Lausanne)       Date:  2022-08-23

Review 6.  Signaling Pathways Related to Oxidative Stress in Diabetic Cardiomyopathy.

Authors:  Meng-Ling Peng; Yu Fu; Chu-Wen Wu; Ying Zhang; Hang Ren; Shan-Shan Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-15       Impact factor: 6.055

7.  Cathepsin B deteriorates diabetic cardiomyopathy induced by streptozotocin via promoting NLRP3-mediated pyroptosis.

Authors:  Chen Liu; Qi Yao; Tongtong Hu; Zhulan Cai; Qingwen Xie; Jinhua Zhao; Yuan Yuan; Jian Ni; Qing Qing Wu
Journal:  Mol Ther Nucleic Acids       Date:  2022-09-23       Impact factor: 10.183
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.